Key result
Edoxaban demonstrated similar or superior efficacy to warfarin for stroke prevention in nonvalvular atrial fibrillation, with a potentially lower risk of major bleeding.
Why the study?
Does edoxaban prevent thromboembolic events in patients with nonvalvular atrial fibrillation?
Population
Patients with nonvalvular atrial fibrillation (NVAF)
Comparison
Edoxaban vs Warfarin
Design
Review
Authors
Loading...
Edoxaban lowers ischemic stroke and major bleeding versus warfarin; reinforces first-line NOAC use in NVAF.
Does edoxaban prevent thromboembolic events in patients with nonvalvular atrial fibrillation?
Edoxaban is an effective and safe alternative to warfarin for stroke prevention in nonvalvular atrial fibrillation, though head-to-head trials with other NOACs are lacking.
Minguet et al. (2016) conducted a review in Nonvalvular atrial fibrillation (NVAF). Edoxaban vs. Warfarin was evaluated. Edoxaban demonstrated similar or superior efficacy to warfarin for stroke prevention in nonvalvular atrial fibrillation, with a potentially lower risk of major bleeding.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: